Her1 vaccine in metastatic colon and prostate cancer

计划入组 88 人

Vaccine HER1 / VSSP for prostate cancer, head and neck carcinoma and advanced colon cancer . Phase I

计划入组 120 人

Gefitinib in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma

计划入组 48 人 · 首次发布于 2003 年 1 月 27 日

tri-specific anti-Her1/Her3 Zybody

Etevritamab

Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells

Herc Holdings

HERA BIOTECH, INC.

United States

HERZ PHARMACEUTICAL TECHNOLOGY PTY LTD

Australia

NERLYNX Launches in Thailand as New HER2+ Breast Cancer Treatment Option

Roche Canada and pCPA Complete Negotiations for Perjeta in Neoadjuvant HER2-Positive Early Breast Cancer

Debiopharm Advances Bispecific ADC Development with SunRock Biopharma's Anti-HER2/HER3 Antibody License